Financials in USD. Standardized financial statements.
A compact view of how Titan Medical Inc. turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $20.09M | $20.00M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $58,064 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $20.09M | $20.00M | -$58,064 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $51.08M | $15.57M | $59.27M | $39.69M | $18.88M | $27.53M | $41.77M | $14.20M | $8.83M | $7.88M |
| Operating Income? | -$14.68M | -$23.09M | -$41.48M | -$22.64M | -$33.59M | -$23.32M | -$41.41M | -$13.45M | -$9.07M | -$7.76M |
| EBITDA? | -$13.98M | -$22.86M | -$41.45M | -$22.61M | -$33.57M | -$23.30M | -$41.38M | -$13.43M | -$8.78M | -$7.63M |
| Income Before Tax | -$14.80M | -$24.18M | -$41.91M | -$22.64M | -$33.59M | -$23.32M | -$41.41M | -$13.45M | -$9.07M | -$7.76M |
| Income Tax Expense | $56,000 | $1.09M | $422,989 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$14.86M | -$25.28M | -$42.33M | -$22.64M | -$33.59M | -$23.32M | -$41.41M | -$13.45M | -$9.07M | -$7.76M |
| EPS? | $-0.22 | $-0.38 | $-1.38 | $-1.36 | $-4.25 | $-4.77 | $-11.92 | $-4.29 | $-3.87 | $-3.63 |
| Diluted EPS? | $-0.22 | $-0.38 | $-1.38 | $-1.36 | $-4.25 | $-4.77 | $-11.92 | $-4.29 | $-3.87 | $-3.63 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality